Published in Vaccine Weekly, May 26th, 1997
The alliance is aimed at developing novel human vaccines for nasal administration thus combining BioVac's expertise in vaccines with Biovector's innovative supra molecular biovector technology currently in development.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly